ENLV
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Enlivex Ltd. (ENLV) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.8) | D+ (1.8) | C- (2.1) | D- (1.0) | C+ (2.6) | C (2.3) |
| 2026-11-04 | B+ (3.8) | C- (1.9) | C- (2.0) | D (1.2) | C+ (2.7) | C (2.3) |
| 2026-10-28 | B+ (3.8) | C- (1.9) | C (2.2) | F (0.3) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | B+ (3.8) | D+ (1.8) | C (2.2) | F (0.3) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | B+ (3.7) | D+ (1.8) | C (2.2) | F (0.3) | C+ (2.6) | C- (2.1) |